Cargando…
RANK and RANK ligand expression in primary human osteosarcoma
Receptor activator of nuclear factor kappa-B ligand (RANKL) is an essential mediator of osteoclast formation, function and survival. In patients with solid tumor metastasis to the bone, targeting the bone microenvironment by inhibition of RANKL using denosumab, a fully human monoclonal antibody (mAb...
Autores principales: | Branstetter, Daniel, Rohrbach, Kathy, Huang, Li-Ya, Soriano, Rosalia, Tometsko, Mark, Blake, Michelle, Jacob, Allison P., Dougall, William C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986823/ https://www.ncbi.nlm.nih.gov/pubmed/27556008 http://dx.doi.org/10.1016/j.jbo.2015.06.002 |
Ejemplares similares
-
RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy
por: Azim, Hatem A, et al.
Publicado: (2015) -
Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
por: Park, Hye-Rim, et al.
Publicado: (2003) -
Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors
por: Szwarc, Maria M., et al.
Publicado: (2015) -
RANK-Ligand inhibitor associated osteonecrosis of the jaw
por: Rashad, Ashkan, et al.
Publicado: (2013) -
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
por: Castellano, Daniel, et al.
Publicado: (2011)